Header Logo

Connection

Frederick Raal to Homozygote

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Homozygote.
Frederick Raal
Connection Strength
7,178
Homozygote
  1. Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
    View in: PubMed
    Score: 0,929
  2. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
    View in: PubMed
    Score: 0,889
  3. Fibroblast growth factor-23 in patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2018 May - Jun; 12(3):767-772.
    View in: PubMed
    Score: 0,582
  4. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):860-869.
    View in: PubMed
    Score: 0,509
  5. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
    View in: PubMed
    Score: 0,509
  6. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
    View in: PubMed
    Score: 0,384
  7. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011 Nov 15; 124(20):2202-7.
    View in: PubMed
    Score: 0,375
  8. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
    View in: PubMed
    Score: 0,235
  9. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
    View in: PubMed
    Score: 0,227
  10. Evinacumab for Homozygous Familial Hypercholesterolemia. Reply. N Engl J Med. 2021 02 11; 384(6):e17.
    View in: PubMed
    Score: 0,179
  11. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
    View in: PubMed
    Score: 0,173
  12. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Jun; 150(2):421-8.
    View in: PubMed
    Score: 0,170
  13. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020 06 02; 141(22):1829-1831.
    View in: PubMed
    Score: 0,170
  14. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis. 2018 10; 277:502-507.
    View in: PubMed
    Score: 0,152
  15. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018 04 07; 39(14):1162-1168.
    View in: PubMed
    Score: 0,147
  16. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
    View in: PubMed
    Score: 0,144
  17. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997 Dec; 135(2):249-56.
    View in: PubMed
    Score: 0,143
  18. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
    View in: PubMed
    Score: 0,141
  19. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
    View in: PubMed
    Score: 0,136
  20. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
    View in: PubMed
    Score: 0,115
  21. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
    View in: PubMed
    Score: 0,107
  22. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013 Apr 24; 2(2):e000028.
    View in: PubMed
    Score: 0,104
  23. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
    View in: PubMed
    Score: 0,084
  24. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
    View in: PubMed
    Score: 0,056
  25. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 01; 44(25):2277-2291.
    View in: PubMed
    Score: 0,053
  26. Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. J Clin Lipidol. 2021 Mar-Apr; 15(2):379-380.
    View in: PubMed
    Score: 0,045
  27. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000 Feb; 20(2):522-8.
    View in: PubMed
    Score: 0,042
  28. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999 Dec 01; 84(11):1344-6, A7.
    View in: PubMed
    Score: 0,041
  29. Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. J Intern Med. 1999 Jul; 246(1):75-80.
    View in: PubMed
    Score: 0,040
  30. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol. 1999 May 01; 83(9):1330-3.
    View in: PubMed
    Score: 0,040
  31. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29; 70(9):1162-1170.
    View in: PubMed
    Score: 0,035
  32. CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet. 1997 Jun; 51(6):394-8.
    View in: PubMed
    Score: 0,035
  33. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21; 36(36):2425-37.
    View in: PubMed
    Score: 0,030
  34. Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. Atherosclerosis. 1995 May; 115(1):9-15.
    View in: PubMed
    Score: 0,030
  35. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21; 35(32):2146-57.
    View in: PubMed
    Score: 0,028
  36. Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. Atherosclerosis. 1994 Jun; 107(2):213-9.
    View in: PubMed
    Score: 0,028
  37. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
    View in: PubMed
    Score: 0,027
  38. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar; 197(1):400-6.
    View in: PubMed
    Score: 0,018
  39. Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia? Clin Chim Acta. 2000 Mar; 293(1-2):105-13.
    View in: PubMed
    Score: 0,010
  40. Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem. 2000 Mar; 37 ( Pt 2):174-8.
    View in: PubMed
    Score: 0,010
  41. Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 1995 Mar; 113(2):289-92.
    View in: PubMed
    Score: 0,007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.